New Directions in Antibacterial, Anticancer, and Gene Editing Therapies

Abstract

Recent advancements in pharmaceutical and gene therapy research have led to the development of novel compounds and delivery systems that target critical areas of unmet medical needs, including drug-resistant bacterial infections, cancer, and genetic diseases. This Patent Highlight reviews the key findings from three recent patents that describe innovations in tricyclic quinolone compounds and adeno-associated virus (AAV) vectors for gene editing. These innovations demonstrate significant progress in the treatment of antibiotic-resistant bacterial infections, BCL6-dependent cancers, and the efficient delivery of CRISPRbased gene editing tools.